Literature DB >> 6108128

Efficacy of some benzodiazepines for day-time sleep.

A N Nicholson, B M Stone, P A Pascoe.   

Abstract

1 Effects of flunitrazepam (0.25-0.50 mg) and the 1,4-triazolodiazepines, triazolam (0.25-0.50 mg) and brotizolam (0.3-0.6 mg), on day time sleep were studied by electroencephalography. 2 Flunitrazepam (0.25-0.50 mg) and triazolam (0.25-0.50 mg) reduced awake activity (P < 0.05) and improved the sleep efficiency index (P < 0.05). The higher dose of each drug increased total sleep time (P < 0.05 and < 0.01 respectively) and duration of stage 2 sleep (P < 0.01), and also delayed the first REM period (P < 0.05 and < 0.01 respectively). 3 Brotizolam (0.6 mg) markedly increased total sleep time (P < 0.001) and the sleep efficiency index (P < 0.01), and prolonged stages 2 (P < 0.01 and slow wave (P < 0.01) sleep. Over the dose range 0.3-0.6 mg, the latency to stage 3 sleep was shortened (P < 0.05), and that to the first REM period lengthened (P < 0.05). 4 All three drugs improved day time sleep. However the present observations and data from previous studies suggest that flunitrazepam (0.25-0.50 mg) may be particularly appropriate for sleep at unusual times.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6108128      PMCID: PMC1430145          DOI: 10.1111/j.1365-2125.1980.tb01789.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Polygraphic sleep recordings before and after the administration of flunitrazepam.

Authors:  U J Jovanović
Journal:  J Int Med Res       Date:  1977       Impact factor: 1.671

2.  Residual effects of flunitrazepam.

Authors:  A J Bond; M H Lader
Journal:  Br J Clin Pharmacol       Date:  1975-04       Impact factor: 4.335

3.  [Change in the mental contents in the paradoxical stage and in stage 2 under the effects of a benzodiazepine, flunitrazepam].

Authors:  J M Gaillard; M Phelippeau
Journal:  Encephale       Date:  1977       Impact factor: 1.291

4.  Immediate and residual effects in man of the metabolites of diazepam.

Authors:  C H Clarke; A N Nicholson
Journal:  Br J Clin Pharmacol       Date:  1978-10       Impact factor: 4.335

5.  Flunitrazepam (Ro 5-4200) and sleep cycle in normal subjects.

Authors:  J M Monti; H Altier
Journal:  Psychopharmacologia       Date:  1973-10-15

6.  Activity of the hypnotics, flunitrazepam and triazolam, in man.

Authors:  A N Nicholson; B M Stone
Journal:  Br J Clin Pharmacol       Date:  1980-02       Impact factor: 4.335

7.  Pharmacokinetics of N-desmethyldiazepam in healthy volunteers after single daily doses of dipotassium chlorazepate.

Authors:  C Post; S Lindgren; A Bertler; H Malmgren
Journal:  Psychopharmacology (Berl)       Date:  1977-07-18       Impact factor: 4.530

Review 8.  Clinical pharmacokinetics of diazepam.

Authors:  M Mandelli; G Tognoni; S Garattini
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

9.  Studies on sleep and performance with a triazolo-1, 4-thienodiazepine (brotizolam).

Authors:  A N Nicholson; B M Stone; P A Pascoe
Journal:  Br J Clin Pharmacol       Date:  1980-07       Impact factor: 4.335

  9 in total
  4 in total

Review 1.  Polysomnographic effects of hypnotic drugs. A review.

Authors:  L Parrino; M G Terzano
Journal:  Psychopharmacology (Berl)       Date:  1996-07       Impact factor: 4.530

2.  The classification of benzodiazepine hypnotics.

Authors:  D M Pierce; R A Franklin
Journal:  Br J Clin Pharmacol       Date:  1983-09       Impact factor: 4.335

3.  Residual effects of repeated doses of 0.5 and 1 mg flunitrazepam.

Authors:  M Lader; A Melhuish; P Harris
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

4.  Human factors and air operations in the South Atlantic campaign: discussion paper.

Authors:  J A Baird; P K Coles; A N Nicholson
Journal:  J R Soc Med       Date:  1983-11       Impact factor: 18.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.